title: Stimulation of thrombopoiesis in mice by fibroblast growth factor 9.
abstract: Fibroblast growth factor 9 (FGF-9), a novel member of the FGF family, was found to have thrombopoietic activity in vitro and in vivo. In an in vitro megakaryocyte colony-stimulating factor assay, anti-mouse interleukin-6 (IL-6) monoclonal antibody neutralized FGF-9 activity. This suggests that the activity may be exerted via IL-6 induction. BALB/c mice that received subcutaneous FGF-9 injections of 4 to 100 micrograms/day for 2 weeks showed a dose-dependent transient increase in peripheral platelet counts 10 to 12 days after the first treatment. Histologic studies showed a marked increase in megakaryocytes in bone marrow and extramedullary hematopoiesis in the spleen and the liver. Examination of changes in the DNA content of bone marrow megakaryocytes revealed that the ploidy distribution underwent a marked shift 3 days after FGF-9 injection, with a large increase in the 2N megakaryocyte population. The major modal ploidy shifted from the normal 16N to 2N. The number of megakaryocyte progenitor cells in FGF-9-treated mice increased up to 1.5-fold in the bone marrow and 10-fold in the spleen on day 6. These results indicate that FGF-9 acts on the in vivo proliferation of megakaryocytes.
authors.affiliation: Department II, Takeda Chemical Industries Ltd, Osaka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Matsumoto-Yoshitomi
authors.forename: C
authors.initials: C
authors.lastname: Seko
authors.forename: K
authors.initials: K
authors.lastname: Kuroshima
authors.forename: K
authors.initials: K
authors.lastname: Naruo
authors.forename: A
authors.initials: A
authors.lastname: Shino
authors.forename: T
authors.initials: T
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Kurokawa
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D001792:Blood Platelets / Q000166:cytology* / Q000187:drug effects; D001854:Bone Marrow Cells; D002455:Cell Division / Q000187:drug effects; D004247:DNA / Q000032:analysis; D051525:Fibroblast Growth Factor 9; D005346:Fibroblast Growth Factors; D006133:Growth Substances / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects*; D006801:Humans; D007279:Injections, Subcutaneous; D015850:Interleukin-6 / Q000096:biosynthesis; D007700:Kinetics; D008533:Megakaryocytes / Q000166:cytology* / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D010976:Platelet Count / Q000187:drug effects*; D011003:Ploidies; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000276:immunology / Q000494:pharmacology; D012016:Reference Values; D013154:Spleen / Q000166:cytology; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; C496459:FGF9 protein, human; C496460:Fgf9 protein, mouse; D051525:Fibroblast Growth Factor 9; D006133:Growth Substances; D015850:Interleukin-6; D011994:Recombinant Proteins; D005346:Fibroblast Growth Factors; D004247:DNA